

RESEARCH SUPPORT OPPORTUNITIES FOR INVESTIGATING CLINICAL OUTCOMES OF MEDICAL MARIJUANA USE



CONSORTIUM FOR
MEDICAL MARIJUANA
CLINICAL OUTCOMES RESEARCH

Marijuana has shown promise in the treatment of certain debilitating conditions, resulting in a growing number of states that have enacted legislature to permit its medical use. Yet, the rapid uptake of medical marijuana is in stark contrast to the scientific evidence supporting its risk-benefit.

The Consortium seeks to advance cutting edge research on the clinical outcomes of medical marijuana to optimize its contribution to public health and there are several ways to support the Consortium's mission.


OVERVIEW

To address the need for rigorous evidence on the safety and effectiveness of medical marijuana, the state legislature introduced Section 1004.4351, Florida Statutes, to establish the Consortium of Medical Marijuana Clinical Outcomes Research to conduct, disseminate and support rigorous scientific research on the clinical effects of medical marijuana.

The University of Florida is the administrative home of the Consortium, which represents a total of nine universities in the state of Florida.

For more information, visit: mmjoutcomes.org

The charter of the Consortium, defines the Consortium purpose as “creating an effective medical marijuana clinical outcomes research program which would mobilize the scientific and medical resources that presently exist in the state to determine the appropriate and best use of marijuana to treat illness”.



Consortium responsibilities as defined in the charter and consistent with statute include:

- Conduct rigorous scientific research
- Disseminate research
- Guide policy for the adoption of a statewide policy on ordering and dosing practices for the medical use of marijuana.

WAYS TO SUPPORT THE CONSORTIUM:

1. Named Research Grant Award

A \$75,000 gift could provide resources for a peer-reviewed research grant award. This is a specific competitive peer-reviewed award with focus on a defined research question/research priority area (consistent with the consortium mission).

Benefits: Research award can carry sponsor name and acknowledgement on the consortium website, in publications and presentations related to this research, or remain anonymous, if so desired.

2. Conference Fund

Funding is needed to support the annual Cannabis Clinical Outcomes Research Conference (CCORC).

With a focus on learning and sharing latest research findings, CCORC aims to provide a forum for researchers, clinicians, policy makers, and other community stakeholders to discuss and advance our understanding of the health effects of medical marijuana.

Support may include:

- Scholarships to attend conference: \$500/person; will cover registration & travel (for students/post-docs/early career scientists based on need).
- Social networking event: any amount towards a total of \$20,000 acknowledged at levels below.

Support for CCORC by sponsors will be acknowledged at the following levels:

- **Gold Level Sponsorship - \$10,000**
Benefits: Secured exhibition booth at annual CCORC, and logo placement/acknowledgement on CCORC program brochure and website; two complementary registrations for CCORC.
- **Silver Level Sponsorship - \$5,000**
Benefits: Two complementary registrations for CCORC; Company/name acknowledged on the CCORC program brochure and on website.
- **Bronze Level Sponsorship - \$2,000**
Benefits: Company/name acknowledged at the CCORC annual conference.

3. Publication Award

Sponsor award funding to recognizing the best paper published by consortium members annually. Winner (\$1,000), and two runners-up (\$500 each).

4. Competitive Grants for Trainees (Graduate Students/Post-doctoral Fellows)

Annual competitive grants program for graduate students/postdoctoral fellows.

A \$10,000 gift could support 2 or more grant proposals.

5. Support Medical Marijuana and Me (M³)

A \$10,000 gift could support a statewide study to characterize experiences and clinical outcomes of medical marijuana patients in Florida

- Support a recruitment location (e.g., compensation for the clinical staff time, space use, tablets for use in clinics): \$2000 per year
- Support a patient (cost to recruit and follow a patient): \$100/participant

6. Unrestricted Contributions to the Consortium Research Program

These funds will be fully devoted to fostering research conducted by the Consortium. Donors will be acknowledged on website or remain anonymous, if desired.

CONTRIBUTIONS, AS SUGGESTED ABOVE, WILL HELP THE CONSORTIUM IN...

Conducting research:

- [Provide financial resources to build the research program](#)
- [Create patient recruitment registry](#) and [collaborate](#)
- [Expand infrastructure involving creating a data repository](#)

Disseminating research:

- [Evidence in context series](#)
- Patient and provider information sheets (*coming soon*)
- [Annual conference](#), [quarterly newsletter](#), [website](#)

RESEARCH PRIORITIES


The Consortium developed research priorities for 2021-2022 based on a comprehensive literature review, national expert panel prioritization, review of statutory mandates, latest inputs from our state-wide physician survey, and a review of NIH areas of programmatic interest.

These research priorities will be applied in both the Consortium's 2021 grants program and will also guide the research projects and proposals directed by Consortium leadership.

Consistent with these research priorities, we have successfully



EARLY OUTPUTS OF THE CONSORTIUM RESEARCH PROGRAM



administered the Research Grants Program for the first two years since the Consortium was established, funding research pertaining to medical marijuana use for several medical conditions. The third grants program cycle is currently underway.

Though early in the research process with only 1 year after the first grants were awarded and despite the COVID-19 pandemic, our awardees and other Consortium researchers have already made great strides.

CONSORTIUM GRANTS PROGRAM: >\$1.2 MILLION AWARDED



FOR MORE INFORMATION:

For making a donation, please contact:

Max Hurley
m.hurley@cop.ufl.edu

Margaret Friend
frienm@shands.ufl.edu

For details about the Consortium programs and initiatives, please contact:

Jeevan Jyot, PhD, PMP
mmjoutcomes@cop.ufl.edu

You are encouraged to contact the Consortium Director:



Almut G Winterstein, RPh, PhD, FISPE

Director, Consortium of Medical Marijuana Clinical Outcomes Research
Distinguished Professor & Chair, Pharmaceutical Outcomes & Policy (POP)
Director, Center for Drug Evaluation and Safety (CoDES)
Dr. Robert and Barbara Crisafi Chair in Medication Safety

1225 Center Drive | Gainesville, FL 32610
P: +1.352.273.6268 | F: +1.352.273.6270
almut@cop.ufl.edu

**Consortium for Medical Marijuana
Clinical Outcomes Research**
PO Box | Gainesville, FL 32610
(352) 273-6984 | mmj.outcomes@cop.ufl.edu



Consortium for
Medical Marijuana
Clinical Outcomes Research

The Consortium for Medical Marijuana Clinical
Outcomes Research, founded by the state of
Florida, represents nine universities in Florida.